Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,499 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押展期及补充质押的公告
Regulatory Filings Classification · 70% confidence The document is a public announcement (公告) concerning the controlling shareholder’s extension of share pledge and supplemental pledge. It contains tables detailing pledged share quantities, pledge periods, and pledgee details. It is not a company buyback or share issuance, nor a proxy or earnings release, and it does not comprise an annual or interim financial report. It also is not a dividend notice or director buying/selling stock. Therefore, this falls under general regulatory filings (RNS) as the catch-all category for mandatory disclosure announcements that do not match other specific filing types.
2026-06-08 Chinese
关于回购股份事项前十名股东和前十名无限售条件股东持股信息的公告
Transaction in Own Shares Classification · 90% confidence The document is an official announcement (公告) by Yifeng Pharma regarding the share repurchase matter, specifically providing details on the top ten shareholders and top ten unrestricted shareholders as of the record date for an extraordinary general meeting to approve the buyback. It follows the listing company share repurchase rules and Shenzhen Stock Exchange guidelines, clearly related to the company's transaction in its own shares. Therefore, it falls under the 'Transaction in Own Shares' category (POS).
2026-06-08 Chinese
关于回购股份事项前十名股东和前十名无限售条件股东持股信息的公告
Transaction in Own Shares Classification · 92% confidence The document is an official announcement by 亿帆医药 regarding its planned share repurchase (“回购股份事项”) and discloses the top ten shareholders and top ten unrestricted shareholders as of the record date for the repurchase. This is regulatory disclosure tied directly to the company’s own shares transaction (share buyback). It is not a high‐level management change, earnings release, or proxy statement, but clearly covers a share repurchase plan. According to the definitions, this falls under “Transaction in Own Shares” (Code: POS).
2026-05-29 Chinese
关于召开2026年第一次临时股东会的通知
Proxy Solicitation & Information Statement Classification · 91% confidence The document is a formal notice convening the 2026 First Extraordinary General Meeting of shareholders, detailing the meeting date, location, agenda proposals, voting methods, proxy authorization form, and registration procedures. It serves as proxy solicitation materials to inform and guide shareholders on how to vote and appoint proxies. This fits the definition of a Proxy Solicitation & Information Statement (PSI) rather than the meeting results, an annual report, or another form.
2026-05-27 Chinese
关于拟注册发行银行间债券市场非金融企业债务融资工具的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement by Yifan Pharma Co., Ltd. regarding the proposed registration and issuance of non-financial enterprise debt financing instruments in the interbank bond market, detailing issuance size, instruments, purposes, board and shareholder authorization, approval procedures, and risk warnings. This is a financing update related to bond issuance, fitting the Capital/Financing Update category rather than a full report or regulatory filing.
2026-05-27 Chinese
关于回购公司股份并用于注销的公告
Transaction in Own Shares Classification · 97% confidence The document is a formal announcement by a listed company detailing a share buyback program: purpose, price range, quantity, funding source, implementation period, and cancellation of repurchased shares. This fits the definition of a Transaction in Own Shares (share repurchase) rather than a financial report or dividend notice.
2026-05-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.